Psyadon Pharma Report issue

For profit Phase 1 Phase 3
Founded: Germantown MD United States (2004)
Status: Acquired by Emalex Biosciences (2018)

Organization Overview

First Clinical Trial
2007
NCT00958503
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ruxton Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

ecopipam (6 trials)

Drugs in Phase 1 Trials (1)

urfamicin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gambling (Phase 2)

Lesch-Nyhan Syndrome (Phase 3)

Self-Injurious Behavior (Phase 3)

Syndrome (Phase 2)

Tourette Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 2